Corso A - Search Results

1

Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.

Mangiacavalli S, Pica G, Varettoni M, Lazzarino M, Corso A. Mangiacavalli S, et al. Among authors: corso a. Eur J Haematol. 2009 Mar;82(3):240-1. doi: 10.1111/j.1600-0609.2008.01184.x. Epub 2008 Nov 10. Eur J Haematol. 2009. PMID: 19018860 No abstract available.

2

Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.

Corso A, Varettoni M, Mangiacavalli S, Zappasodi P, Pica GM, Algarotti A, Pascutto C, Lazzarino M. Corso A, et al. Eur J Haematol. 2009 Nov;83(5):449-54. doi: 10.1111/j.1600-0609.2009.01295.x. Epub 2009 Jun 10. Eur J Haematol. 2009. PMID: 19519727

3

Changes in multiple myeloma epidemiology in the last thirty years: a single centre experience.

Zappasodi P, Corso A, Klersy C, Pica G, Mangiacavalli S, Varettoni M, Rusconi C, Pascutto C, Lazzarino M. Zappasodi P, et al. Among authors: corso a. Eur J Cancer. 2006 Feb;42(3):396-402. doi: 10.1016/j.ejca.2005.09.031. Epub 2006 Jan 5. Eur J Cancer. 2006. PMID: 16403623

4

Thrombomodulin levels are not modified during thalidomide treatment.

Zappasodi P, Mangiacavalli S, Terulla V, Airò F, Klersy C, Varettoni M, Corso A. Zappasodi P, et al. Among authors: corso a. Eur J Haematol. 2006 Nov;77(5):453-4. doi: 10.1111/j.1600-0609.2006.00733.x. Eur J Haematol. 2006. PMID: 17044838 No abstract available.

5

The impact of new emerging drugs in the treatment of multiple myeloma: is there still a role for PBSC transplantation?

Corso A, Varettoni M. Corso A, et al. Curr Stem Cell Res Ther. 2007 Jan;2(1):1-11. doi: 10.2174/157488807779316955. Curr Stem Cell Res Ther. 2007. PMID: 18220887 Review.

6

Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.

Corso A, Zappasodi P, Barbarano L, Petrucci MT, Palumbo A, Caravita T, Mangiacavalli S, Cafro AM, Varettoni M, Gay F, Morra E, Lazzarino M. Corso A, et al. Leuk Res. 2009 Sep;33(9):e145-9. doi: 10.1016/j.leukres.2009.03.015. Epub 2009 Apr 16. Leuk Res. 2009. PMID: 19375164

7

Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.

Mangiacavalli S, Corso A, De Amici M, Varettoni M, Alfonsi E, Lozza A, Lazzarino M. Mangiacavalli S, et al. Among authors: corso a. Br J Haematol. 2010 Jun;149(6):916-8. doi: 10.1111/j.1365-2141.2010.08138.x. Epub 2010 Mar 1. Br J Haematol. 2010. PMID: 20201942 Free article. Clinical Trial. No abstract available.

8

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients.

Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Varettoni M, et al. Among authors: corso a. Ann Oncol. 2010 Feb;21(2):325-330. doi: 10.1093/annonc/mdp329. Epub 2009 Jul 24. Ann Oncol. 2010. PMID: 19633044 Free article.

9

Advantages of using thalidomide for the management of refractory myeloma patients.

Corso A, Lorenzi A, Orlandi E, Astori C, Mangiacavalli S, Lazzarino M. Corso A, et al. Haematologica. 2002 Mar;87(3):327-8. Haematologica. 2002. PMID: 11869949

10

Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.

Zappasodi P, Dore R, Castagnola C, Astori C, Varettoni M, Mangiacavalli S, Lazzarino M, Corso A. Zappasodi P, et al. Among authors: corso a. J Clin Oncol. 2007 Aug 1;25(22):3380-1. doi: 10.1200/JCO.2006.10.0164. J Clin Oncol. 2007. PMID: 17664489 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

476 results

Search Page

Filters